ALK-Abelló (ALK) CMD 2024 summary

Strategy and Future Focus

• Launched the Allergy+ strategy, aiming to double annual patients treated from 2.4 million to 5 million by 2030, with a focus on pediatric launches, food allergy, and anaphylaxis markets.

• Targets minimum 10% average annual revenue growth through 2028, with EBIT margin reaching ~25% by 2025 and maintained through 2028.

• Prioritizes capital allocation to organic growth, R&D (up to 15% of revenue), CAPEX, and business development, with shareholder returns as a third priority.

• Expands leadership in allergy immunotherapy, invests in digital infrastructure and AI, and reallocates resources from underperforming areas.

• Sustainability and diversity remain core, with a commitment to CO2 reduction and an inclusive work environment.

Market and Growth Drivers

• Maintains a strong global position in AIT, with a 45% market share and ambitions to surpass 50%, driven by SLIT-tablets and pediatric indications.

• Europe is the main growth driver, with significant opportunities in pediatric and digital engagement; Japan and China are key international markets, focusing on pediatric patients and hospital expansion.

• North America faces challenges due to entrenched practices, but targeted efforts focus on pediatricians and enterprise models, with Canada showing strong growth.

• Adjacent areas like food allergy and anaphylaxis are targeted for future leadership, leveraging existing channels and expertise.

• Strategic partnerships in Japan, China, and with academic institutions accelerate innovation and market access.

R&D and Pipeline Development

• R&D vision centers on expanding leadership in respiratory allergy, building a balanced pipeline, and accelerating innovation through internal development and external partnerships.

• Pipeline includes pediatric label expansions, next-generation autoinjector (Genesis), and a peanut SLIT-tablet in clinical development, with ambitions to broaden into non-allergen-specific and biologic therapies.

• AI and data-driven approaches are prioritized to enhance discovery, accelerate development, and optimize clinical outcomes.

• Recognizes a mid-term pipeline gap and is actively seeking external assets, especially in early clinical and preclinical stages.

• Regulatory milestones targeted for ACARIZAX® in China and India, and GRAZAX® in Japan.